Brett Busch

Brett Busch, Ph.D. has extensive work experience in the field of medicinal chemistry. Brett is currently working as the Senior Director of Medicinal Chemistry at Genesis Therapeutics, starting in January 2022. Prior to this, they served as a Principal Scientist at Inception Sciences, Inc. from December 2019 to January 2022.

From July 2010 to December 2019, Brett held the position of Senior Scientist Medicinal Chemist at Vertex Pharmaceuticals. In this role, they contributed to various projects in the cardiovascular and metabolic disease area, developing small molecule modulators of LXR, ERRa, and FXR. Their work played a vital role in the development of several Phase I clinical candidates.

Before joining Vertex Pharmaceuticals, Brett worked at Exelixis, Inc. as a Senior Scientist I, Medicinal Chemist from an unspecified start date until May 2010. During this time, they worked on multiple projects related to cardiovascular and metabolic diseases, designing molecular templates to achieve the desired potency, SAR, PK, and ADME profile.

Brett's earlier experience includes working as a Research Scientist/Medicinal Chemist at X-ceptor Therapeutics from an unspecified start date until September 2004. Here, they played a significant role in the development of novel small molecule modulators for orphan nuclear hormone receptors, particularly contributing to the invention of the commercial compound, XCT790, during the ERRa project.

Brett Busch, Ph.D. completed their education with a B.S. degree in Chemistry from The University of Texas at Austin. Brett further pursued their studies at UC Irvine, where they earned a Ph.D. in Organic Chemistry.